In patients with EGFR-mutant NSCLC and MET amplification with disease progression on EGFR TKI treatment, subsequent treatment with an MET inhibitor and EGFR-TKI combination rendered clinical benefits in a series of phase I/II studies (Table 1) [71,72,73,94,95,96,97,98,99,100,101]. This evidence concerns the gene MET and non-small cell lung carcinoma.